clinical trial · NCT05918627
A Study to Determine the Effect of Multiple Oral Doses of SLx-2119 in Healthy Male Subjects
Kadmon, a Sanofi Company·phase1·completed·n = 32
Immune System Disorder (Healthy Volunteer)Belumosudil mesylatePlacebo
brief summary
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of multiple doses of SLx-2119 in healthy male participants.
started
Sep 21, 2009
primary completion
Dec 9, 2009
completion
Dec 9, 2009
last updated
Jun 26, 2023
detailed description
Duration per participants is Day 1 up to 30 days after participant is treated with the last dose of study drug.
official title
A Randomized, Double-blind, Placebo-controlled, Dose Escalating Study to Examine the Safety, Tolerability and Pharmacokinetic Profile of Single Oral Doses of SLx-2119 in Healthy Male Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol